Description
Mod GRF 1-29 & GHRP-6 Peptide Blend
GHRP-6 (Growth Hormone Releasing Peptide-6) is a man-made peptide designed to promote growth hormone release from the pituitary gland by acting similarly to ghrelin. It is classified as a growth hormone secretagogue (GHS) and ghrelin mimetic. Structurally, it is a hexapeptide made up of six amino acids. Research has explored its potential use in conditions such as growth hormone deficiency and muscle-wasting states like cachexia.
Modified GRF 1-29, also known as CJC-1295 without DAC, is a synthetic analog of growth hormone-releasing hormone (GHRH). It consists of 29 amino acids and represents a shortened, modified version of the GRF 1-29 fragment. This fragment is considered the minimal portion of GHRH needed to stimulate growth hormone release.
Chemical Composition
Molecular formulas:
- Mod GRF 1-29: C152H252N44O42
- GHRP-6: C46H56N12O6
Molecular weights:
- Mod GRF 1-29: 3367.95 g/mol
- GHRP-6: 873.03 g/mol
Also known as:
- Mod GRF 1-29: CJC-1295 (no DAC), tetrasubstituted GRF 1-29
- GHRP-6: Growth Hormone Releasing Peptide-6
Mechanism and Research Overview
Mod GRF 1-29 and GHRP-6 are thought to influence growth hormone and IGF-1 levels by acting on different receptors. Mod GRF 1-29 is believed to bind to GHRH receptors on pituitary somatotroph cells, triggering intracellular signaling pathways that may lead to growth hormone release. This process is thought to involve activation of adenylyl cyclase, increased cAMP production, activation of protein kinase A, and subsequent phosphorylation of proteins that regulate calcium channels. The resulting increase in intracellular calcium is believed to promote growth hormone secretion.
GHRP-6, on the other hand, is thought to act through the ghrelin receptor (GHS-R1a). Binding to this receptor may activate signaling pathways involving phospholipase C (PLC), leading to production of IP3 and DAG. These messengers can increase intracellular calcium release, which may also stimulate growth hormone secretion.
Possible Synergistic Effects
Research suggests that combining GHRP-6 with Mod GRF 1-29 may produce a stronger growth hormone response than either peptide alone. This may be because each acts through different receptors and possibly different stages of hormone release.
Some studies report higher increases in IGF-1 when both compounds are used together compared to single-agent use. Experimental findings also suggest that combining GHRH analogs with GHRPs may significantly amplify pulsatile growth hormone secretion, indicating potential synergy between the two mechanisms.
Effects on Muscle and Body Composition
Both peptides have been studied for their possible effects on body composition through increased growth hormone and IGF-1 production. GRF 1-29 has been associated in some studies with increases in lean body mass, skin thickness, and insulin sensitivity.
Older adult studies have shown improvements in muscle strength, endurance, and hormone levels following GRF 1-29 administration. GHRP-6 has also been linked to anabolic-like effects in laboratory studies, including increased expression of muscle-related proteins and collagen production.
Growth Hormone Deficiency Research
Both peptides have been investigated in the context of growth hormone deficiency. In clinical research, GRF 1-29 has been shown to increase growth velocity in a majority of treated subjects over extended periods, while maintaining stable metabolic markers.
GHRP-6 has also demonstrated the ability to stimulate growth hormone release in human studies, with effects similar to other secretagogue compounds.
Cachexia and Catabolic Conditions
Mod GRF 1-29 and GHRP-6 may have potential anti-catabolic effects due to their ability to raise GH and IGF-1 levels. These effects are being explored in conditions involving muscle loss and wasting.
Studies on GHRP-6 suggest it may strongly stimulate growth hormone release, particularly in certain populations, and may be more effective than GHRH alone in some cases. Ghrelin mimetics in general have been studied for their potential to improve appetite, body composition, and energy balance, and may also influence inflammation and mood-related pathways.
Research Use Statement
This peptide blend is intended for laboratory and research purposes only, and is not approved for medical use in humans.
Reviews
There are no reviews yet.